Download PDF
Semin Respir Crit Care Med 2025; 46(01): 014-019
DOI: 10.1055/a-2592-0735
Review Article

Pertussis Vaccination: The Challenges Ahead

Nicole Guiso
1   Independent Medical Expert Consulting Services Inc, Paris, France
,
Carl Heinz Wirsing von Koenig
2   Independent eMedical Expert Consulting, Krefeld, Germany
› Author Affiliations
Funding None.
› Further Information
   Permissions and Reprints

Abstract

Pertussis, a highly contagious respiratory disease, is preventable with vaccine. Two types of vaccines are used around the world: whole-cell pertussis vaccines (wP), which contain inactivated bacterial suspensions are difficult to produce and induce some side effects, and acellular pertussis vaccines (aP), which contain one to five purified bacterial antigens, chemically or genetically detoxified. Both the vaccines succeeded in massively decreasing child deaths caused by pertussis. However, irrespective of vaccination, the disease is still endemic around the world, and cycles of pertussis are still observed every 3 to 5 years in both wP- or aP-vaccinated regions. The interval between each cycle, and the intensity and incidence of the disease during these cycles vary. The first challenge ahead is to rapidly increase vaccine coverage by vaccinating infants on time, introducing regular vaccine boosters throughout life, and vaccinating pregnant women. The second challenge is to introduce an effective disease surveillance such as a pediatric hospital surveillance, allowing an estimation of the incidence of severe disease in the pediatric population, and/or a sentinel surveillance, allowing to detect changes in the incidence of the disease in the population. All surveillance systems require a functional network of physicians in the country aware of the clinical forms of the disease in children, adolescents, adults, and seniors. Surveillance is required to adapt vaccine strategies according to the vaccine type and to follow the evolution of the agents of the disease. The third challenge is to pursue research to improve these vaccines. However, before changing vaccines once again, an evaluation of the exact consequences of aP or wP vaccines under specific vaccine strategies needs to be carefully carried out.

Keywords

pertussis - vaccines - vaccine strategy


Publication History

Article published online:
06 June 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Cherry JD, Tan T, Wirsing von König CH. et al. Clinical definitions of pertussis: summary of a global pertussis initiative roundtable meeting, February 2011. Clin Infect Dis 2012; 54 (12) 1756-1764
    PubMedSearch in Google Scholar
  • 2 Liu BC, McIntyre P, Kaldor JM, Quinn HE, Ridda I, Banks E. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis 2012; 55 (11) 1450-1456
    PubMedSearch in Google Scholar
  • 3 Bordet JGengou O. Le microbe de la coqueluche. Ann Inst Pasteur (Paris) 1906; 20: 731-741
    PubMedSearch in Google Scholar
  • 4 Eldering G, Kendrick P. Bacillus para-pertussis: a species resembling both Bacillus pertussis and Bacillus bronchisepticus but identical with neither. J Bacteriol 1938; 35 (06) 561-572
    PubMedSearch in Google Scholar
  • 5 Aslanabadi A, Ghabili K, Shad K, Khalili M, Sajadi MM. Emergence of whooping cough: notes from three early epidemics in Persia. Lancet Infect Dis 2015; 15 (12) 1480-1484
    PubMedSearch in Google Scholar
  • 6 Lapin JH. Whooping Cough. Springfield, IL: Charles C Thomas Publisher; 1943
    Search in Google Scholar
  • 7 Bart MJ, Harris SR, Advani A. et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio 2014; 5 (02) e01074
    PubMedSearch in Google Scholar
  • 8 Novotny P. Pathogenesis in Bordetella species. J Infect Dis 1990; 161 (03) 581-583
    PubMedSearch in Google Scholar
  • 9 Mbayei SA, Faulkner A, Miner C. et al. Severe pertussis infections in the United States, 2011–2015. Clin Infect Dis 2019; 69 (02) 218-226
    PubMedSearch in Google Scholar
  • 10 Karki S, McIntyre P, Newall AT, MacIntyre CR, Banks E, Liu B. Risk factors for pertussis hospitalizations in Australians aged 45 years and over: a population based nested case-control study. Vaccine 2015; 33 (42) 5647-5653
    PubMedSearch in Google Scholar
  • 11 WHO Laboratory Manual for the Diagnosis of Whooping Cough Caused by Bordetella pertussis/Bordetella parapertussis: Update 2014. World Health Organization; 2014. Accessed at: http://www.who.int/iris/handle/10665/127891
    PubMed
  • 12 Ivaska L, Barkoff AM, Mertsola J, He Q. Macrolide resistance in Bordetella pertussis: current situation and future challenges. Antibiotics (Basel) 2022; 11 (11) 1570
    CrossrefPubMedSearch in Google Scholar
  • 13 Tizolova A, Guiso N, Guillot S. Insertion sequences shared by Bordetella species and implications for the biological diagnosis of pertussis syndrome. Eur J Clin Microbiol Infect Dis 2013; 32 (01) 89-96
    PubMedSearch in Google Scholar
  • 14 Nguyen LB, Epelboin L, Gabarre J. et al. Recurrent Bordetella holmesii bacteremia and nasal carriage in a patient receiving rituximab. Emerg Infect Dis 2013; 19 (10) 1703-1705
    PubMedSearch in Google Scholar
  • 15 Guiso N, Berbers G, Fry NK, He Q, Riffelmann M, Wirsing von König CH. EU Pertstrain group. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011; 30 (03) 307-312
    PubMedSearch in Google Scholar
  • 16 Guiso N, Meade BD, Wirsing von König CH. Pertussis vaccines: the first hundred years. Vaccine 2020; 38 (05) 1271-1276
    PubMedSearch in Google Scholar
  • 17 Baron S, Njamkepo E, Grimprel E. et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998; 17 (05) 412-418
    PubMedSearch in Google Scholar
  • 18 Bordet J, Sleeswijk JG. Sérodiagnostic et variabilité des microbes suivant le milieu de culture. Ann Inst Pasteur (Paris) 1910; 24 (06) 476-494
    PubMedSearch in Google Scholar
  • 19 Bass JW, Stephenson SR. The return of pertussis. Pediatr Infect Dis J 1987; 6 (02) 141-144
    PubMedSearch in Google Scholar
  • 20 Wirsing von König CH, Campins-Marti M, Finn A, Guiso N, Mertsola J, Liese J. Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005; 24 (5, suppl): S87-S92
    PubMedSearch in Google Scholar
  • 21 Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24 (5, suppl): S58-S61
    CrossrefPubMedSearch in Google Scholar
  • 22 Edwards KM, Decker M. Pertussis vaccines. In: Orenstein WA, Offit PA, Edwards KM, Plotkin SA. eds. Plotkin's Vaccines. 8th ed.. Philadelphia, PA: Elsevier; 2022
    Search in Google Scholar
  • 23 Ward JI, Cherry JD, Chang SJ. et al; APERT Study Group. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353 (15) 1555-1563
    PubMedSearch in Google Scholar
  • 24 Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis 2014; 209 (07) 978-981
    PubMedSearch in Google Scholar
  • 25 Amirthalingam G, Campbell H, Ribeiro S. et al. Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. Clin Infect Dis 2016; 63 (Suppl. 04) S236-S243
    PubMedSearch in Google Scholar
  • 26 Skoff TH, Deng L, Bozio CH, Hariri S. US infant pertussis incidence trends before and after implementation of the maternal tetanus, diphtheria, and pertussis vaccine JAMA Pediatr 2023; 177 (04) 395-400
    PubMedSearch in Google Scholar
  • 27 European Centre for Disease Prevention and Control (ECDC). Communicable disease threats report. Accessed at: https://www.ecdc.europa.eu/en/publications-data/increase-pertussis-cases-eueea
    PubMed
  • 28 WHO. Pertussis: Surveillance Standards. Accessed at: www.who.int/vaccines-documents
    PubMed
  • 29 Guiso N, Wirsing von König CH. Surveillance of pertussis: methods and implementation. Expert Rev Anti Infect Ther 2016; 14 (07) 657-667
    PubMedSearch in Google Scholar
  • 30 Wirsing von Koenig CH. Pertussis: point-of-care testing in the making. EClinicalMedicine 2019; 8: 4-5
    PubMedSearch in Google Scholar
  • 31 Yılmaz Çolak Ç. Microfluidic point-of-care testing for the detection of Bordetella pertussis: a mini-review. Diagn Microbiol Infect Dis 2024; 109 (02) 116239
    PubMedSearch in Google Scholar
  • 32 Guiso N, Soubeyrand B, Macina D. Can vaccines control bacterial virulence and pathogenicity? Bordetella pertussis: the advantage of fitness over virulence. Evol Med Public Health 2022; 10 (01) 363-370
    PubMedSearch in Google Scholar
  • 33 Hegerle N, Paris A-S, Brun D. et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect 2012; 18 (09) E340-E346
    PubMedSearch in Google Scholar
  • 34 Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine 2009; 27 (43) 6034-6041
    PubMedSearch in Google Scholar
  • 35 Barkoff AM, Mertsola J, Pierard D. et al. Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015. Euro Surveill 2019; 24 (07) 1700832
    PubMedSearch in Google Scholar
  • 36 UNICEF report. Accessed at: https://www.unicef.org/reports/state-of-worlds-children
    PubMed
  • 37 WHO. (2015) Pertussis vaccines: WHO position paper. Accessed at: https://www.who.int/wer/2015/wer9035
    PubMed
  • 38 Dellepiane N, Pagliusi S. Registration Experts Working Group. Challenges for the registration of vaccines in emerging countries: differences in dossier requirements, application and evaluation processes. Vaccine 2018; 36 (24) 3389-3396
    PubMedSearch in Google Scholar
  • 39 Verdier R, Marchal C, Belhassen M, Pannerer ML, Guiso N, Cohen R. Coverage rates for diphtheria, tetanus, poliomyelitis, and pertussis age-specific booster recommendations in France: 2018 update of the real-world cohort analysis. Infect Med (Beijing) 2022; 2 (01) 51-56
    PubMedSearch in Google Scholar
  • 40 Lu PJ, Hung MC, Srivastav A. et al. Surveillance of vaccination coverage among adult populations—United States, 2018. MMWR Surveill Summ 2021; 70 (03) 1-26
    CrossrefPubMedSearch in Google Scholar
  • 41 CDC. Current Vaccine Shortages and Delays. Accessed May 1, 2025 at: https://www.cdc.gov/vaccines/hcp/vaccines-us/shortages-delays.html
    PubMed
  • 42 Patterson J, Kagina BM, Gold M, Hussey GD, Muloiwa R. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: a systematic review. Vaccine 2018; 36 (40) 6007-6016
    PubMedSearch in Google Scholar
  • 43 Sricharoenchai S, Sirivichayakul C, Chokephaibulkit K. et al. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. Lancet Infect Dis 2018; 18 (01) 58-67
    PubMedSearch in Google Scholar
  • 44 Chaithongwongwatthana S, Wijagkanalan W, Wanlapakorn N. et al. Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: real-world evidence. Int J Infect Dis 2024; 144: 107047
    PubMedSearch in Google Scholar
  • 45 Keech C, Miller VE, Rizzardi B. et al. Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Lancet 2023; 401 (10379): 843-855
    CrossrefPubMedSearch in Google Scholar
  • 46 Thalen M, Debrie AS, Coutte L. et al. Manufacture of a stable lyophilized formulation of the live attenuated pertussis vaccine BPZE1. Vaccines (Basel) 2020; 8 (03) 523
    PubMedSearch in Google Scholar
  • 47 Guiso N. Bordetella adenylate cyclase-hemolysin toxins. Toxins (Basel) 2017; 9 (09) 277
    PubMedSearch in Google Scholar
  • 48 Hozbor DF. Outer membrane vesicles: an attractive candidate for pertussis vaccines. Expert Rev Vaccines 2017; 16 (03) 193-196
    PubMedSearch in Google Scholar
  • 49 Pulendran B, S. Arunachalam P, O'Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov 2021; 20 (06) 454-475
    PubMedSearch in Google Scholar